文献速递冠心病

ACS后短暂达到极低LDL-C水平与心血管风险降低相关:ODYSSEY OUTCOMES试验

Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
PubMed 文献 · Eur Heart J · 2023-03-05

ODYSSEY OUTCOMES试验纳入18,924例急性冠脉综合征后患者,比较阿利西尤单抗与安慰剂(均联合高强度或最大耐受他汀)。事后分析中,73例阿利西尤单抗组患者因连续两次LDL-C<0.39 mmol/L而盲法换用安慰剂,与1460例倾向评分匹配的安慰剂组患者比较,中位随访2.8年,主要不良心血管事件风险降低(HR 0.72;95%CI 0.51, 0.997;P=0.047)。

要点

  • ACS后短暂达到LDL-C<0.39 mmol/L并随后仅用他汀,与MACE风险降低相关
  • 该获益在观察期内持续数年,提示存在遗留效应
  • 事后分析结果需谨慎解读,样本量有限

核心结论

  • 短时间达到LDL-C<0.39 mmol/L(他汀联合阿利西尤单抗)后改用他汀单药,与整个观察期内MACE风险低于他汀单药相关,临床获益持续数年。

研究设计与样本

  • ODYSSEY OUTCOMES试验的事后分析,纳入18,924例急性冠脉综合征后患者,比较阿利西尤单抗与安慰剂(均联合高强度或最大耐受他汀)。
  • 阿利西尤单抗组中连续两次LDL-C<0.39 mmol/L(15 mg/dL)的730例患者盲法换用安慰剂并继续他汀,与1460例倾向评分匹配的安慰剂组患者比较。

主要发现

  • 阿利西尤单抗组730例患者在中位随机化后8.3个月换用安慰剂,此前LDL-C<0.39 mmol/L的中位持续时间为6.0个月。
  • 中位随访2.8年,主要不良心血管事件在短暂极低LDL-C的阿利西尤单抗组发生47例(6.4%),匹配安慰剂组122例(8.4%)(治疗风险比0.72;95%CI 0.51, 0.997;P=0.047)。
  • 两组基线LDL-C和脂蛋白(a)均较低,研究药物依从性优于总体队列。

关键数值与推荐

  • LDL-C阈值:连续两次<0.39 mmol/L(15 mg/dL)触发盲法安慰剂替换。
  • 主要不良心血管事件:阿利西尤单抗组6.4% vs 匹配安慰剂组8.4%,HR 0.72(95%CI 0.51, 0.997),P=0.047。

临床怎么用

  • 对于ACS后接受他汀联合PCSK9抑制剂达到极低LDL-C的患者,短暂极低水平后改用他汀单药仍可能带来持续的心血管获益。
  • 临床决策中可考虑极低LDL-C目标的短期达标策略,但需结合个体风险评估。

局限性

  • 为事后分析,非预设主要分析,存在残余混杂可能。
  • 换用安慰剂的患者样本量有限(730例),事件数较少。
  • 仅代表特定试验人群和方案,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Long-term, placebo-controlled cholesterol-lowering trials have demonstrated legacy effects (clinical benefits that persist or emerge after trial end). It is unknown whether legacy effects follow a short period of very low low-density lipoprotein cholesterol (LDL-C) levels achieved with statin plus PCSK9 inhibitor. METHODS AND RESULTS: In 18,924 patients post-acute coronary syndrome, the ODYSSEY OUTCOMES trial compared the PCSK9 inhibitor alirocumab with placebo, each added to high-intensity or maximum-tolerated statin therapy. Patients with two consecutive LDL-C levels <0.39 mmol/L (15 mg/dL) on alirocumab had blinded placebo substitution for the remainder of the trial with continued statin treatment. In post hoc analyses, major adverse cardiovascular events (MACE) in these patients were compared to MACE in propensity score-matched patients from the placebo group with similar baseline characteristics and study medication adherence. In the alirocumab group, 730 patients had blinded placebo substitution at a median 8.3 months from randomization, after a median 6.0 months with LDL-C < 0.39 mmol/L. They were matched to 1460 placebo patients. Both groups had lower baseline LDL-C and lipoprotein(a) and better study medication adherence than the overall cohort. Over a median follow-up of 2.8 years, MACE occurred in 47 (6.4%) alirocumab patients with limited-duration, very low achieved LDL-C versus 122 (8.4%) matched placebo patients (treatment hazard ratio 0.72; 95% confidence interval 0.51, 0.997; P = 0.047). CONCLUSIONS: A short period of LDL-C levels <0.39 mmol/L achieved with statin and alirocumab, followed by statin monotherapy, was associated with lower risk of MACE than statin monotherapy throughout the observation period. Clinical benefit persisted for several years. TRIAL REGISTRATION: ClinicalTrials.gov NCT01663402.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Schwartz, Szarek, Bhatt, et al. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. Eur Heart J. 2023. PMID: 36879424. doi:10.1093/eurheartj/ehad144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。